CTM Form 4: Director awarded 100,000 stock options at $1.19
Rhea-AI Filing Summary
Castellum, Inc. (CTM) reported a director equity grant. On 11/11/2025, director C. Thomas McMillen was granted 100,000 stock options with an exercise price of $1.19 per share under the Second Amended 2021 Stock Incentive Plan.
The options relate to 100,000 shares of common stock, vesting ratably over twenty months commencing December 1, 2025, and expiring on 11/10/2032. Following the grant, 100,000 derivative securities were beneficially owned, held directly. The filing classifies the transaction as an acquisition of derivative securities as compensation for board service.
Positive
- None.
Negative
- None.
Insights
Routine director option grant; neutral governance event.
Castellum granted 100,000 options at an exercise price of $1.19 to director C. Thomas McMillen on 11/11/2025. The award vests ratably over twenty months starting December 1, 2025 and expires on 11/10/2032. This aligns with standard board compensation structures.
The disclosure indicates 100,000 derivative securities beneficially owned following the transaction, held directly. As a routine equity grant for service, this is administratively neutral for valuation; any impact depends on future vesting and market price at potential exercise.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 100,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. As compensation for his service as an independent member of the Board of Directors, Mr. McMillen received 100,000 stock options granted pursuant to the terms of the Castellum, Inc. Second Amended 2021 Stock Incentive Plan to purchase 100,000 shares of common stock which vest ratably over a period of twenty months commencing December 1, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.